Tag: CYP

ASX biotech stocks COVID-19 life science

ASX biotech stocks benefiting from the COVID-19 story

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Natural...
Cynata Therapeutics ASX CYP clinical trial COVID-19 ethics approval Cymerus mesenchymal stem cells MSCs

Cynata Therapeutics gets approval for clinical trial on COVID-19

Biotechnology company Cynata Therapeutics (ASX: CYP) intends to develop a treatment for COVID-19 by repurposing its Cymerus mesenchymal stem cells (MSCs) products and research. In a statement to th...
Cynata Therapeutics ASX CYP tax incentive refund COVID-19 infection mesenchymal stem cells

Cynata Therapeutics’ stem cells could potentially help treat severe COVID-19 symptoms

Cynata Therapeutics (ASX: CYP) revealed it is in “active discussions” with international pharmaceutical companies and other parties regarding using its Cymerus mesenchymal stem cell (MSC) platform to ...
Cynata Therapeutics ASX CYP sepsis blood poisoning Cymerus mesenchymal stem cells regenerative medicine MSC

Cynata Therapeutics has positive pre-clinical results using Cymerus stem cell platform to treat sepsis

Pre-clinical studies using Cynata Therapeutics’ (ASX: CYP) Cymerus mesenchymal stem cells in a sepsis model have achieved positive results. In a pre-clinical model of severe pneumonia-induced sepsi...
Cynata Therapeutics ASX CYP Fujifilm graft-versus-host disease GvHD mesenchymal stem cell MSC CYP-001

Fujifilm to commercialise Cynata Therapeutics’ mesenchymal stem cell technology

Following a successful phase one clinical trial, FUJIFILM Corporation (Fujifilm) has exercised its option to commercialise Cynata Therapeutics’ (ASX: CYP) mesenchymal stem cell product which can treat...
Cynata Therapeutics ASX CYP Cymerus mesenchymal stem cells MSCs preclinical trial glioblastoma brain cancer melanoma

Cynata Therapeutics reveals more positive pre-clinical cancer trial results

Biotechnology company Cynata Therapeutics (ASX: CYP) has published encouraging results from its ongoing preclinical program using its proprietary Cymerus platform. The company said it was able to s...
Cynata Therapeutics ASX CYP Cymerus stem cell treatment phase 1 trial

Cynata Therapeutics looks to advance Cymerus stem cell treatment into phase 2 trials

Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has said that it has “met all clinical endpoints” in its phase 1 trial of flagship drug CYP-001 – for the treatment of steroi...
Cynata Therapeutics ASX CYP stem cells regenerative medicine positive efficacy data study Cymerus mesenchymal MSCs heart attack

Cynata study shows positive link between stem cells and cardiac function post-heart attack

Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has announced positive efficacy data from a study of its Cymerus mesenchymal stem cells (MSCs) in a pre-clinical heart attack...
Cynata Therapeutics ASX CYP phase two trial bone marrow graft vs host disease

Phase 2 bone marrow transplant drug trial on the horizon for Cynata Therapeutics

Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) may advance to a phase 2 clinical trial of a new stem cell drug if results of an initial two-stage trial continue ...
Cynata Therapeutics ASX CYP coronary artery disease heart stem cell therapy research

Cynata includes coronary artery disease into existing stem cell therapy research platform

Regenerative medicine company Cynata Therapeutics (ASX: CYP) has partnered up with the University of New South Wales (UNSW) in a bid to develop a stem cell treatment for coronary artery disease (CAD) ...
Cynata Therapeutics ASX CYP granted Notice of Allowance from European Patent Office

Cynata Therapeutics receives notice of allowance ahead of patent for stem cell platform

A patent covering a stem cell technology platform developed by Cynata Therapeutics (ASX: CYP) appears on the horizon, following the receipt of a Notice of Allowance from the European Patent Office (EP...
Cynata Therapeutics ASX CYP Cymerus patent stem cell technology

Cynata Therapeutics finalises Cymerus patent to treat adverse reactions to cancer immunotherapy

Cynata Therapeutics (ASX: CYP) has wrapped up an IP Australia patent application for therapeutic use of its Cymerus stem cell technology in treating adverse reactions from chimeric antigen receptor T-...
Cynata Therapeutics ASX CYP Orphan Drug Designation FDA graft versus host disease bone marrow

Cynata receives key FDA approval to progress GvHD drug candidate

For the second time in as many days, the US Food and Drug Administration (FDA) has granted important permission to an ASX-listed company in the biotech space. On this occasion, the FDA granted Cyna...
Cynata Therapeutics ASX CYP trial stem cells treating graft versus host disease

Cynata unveils promising results in treating graft versus host disease with stem cells

Cynata Therapeutics (ASX: CYP) has unveiled “excellent” data from its “world first” clinical trial using its stem cell product CYP-001 in treating steroid resistant graft versus host disease. After...
Cynata Therapeutics ASX CYP Celularity Cymerus

Cynata finds synergy with US-based biotech developer

Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has signed a Memorandum of Understanding (MoU) with Celularity Inc., a US-based biotech company focusing on regene...
Cynata Therapeutics ASX CYP clinical trial mesenchymal stem cells

Cynata Therapeutics advance to second cohort in stem cell trial

Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has received an encouraging early response from the clinical trials of its stem cell product CYP-001, which began in November...
Cynata Therapeutics CYP ASX clinical trial stem cell graft versus host disease

Cynata Therapeutics enrols first cohort for world first clinical trial

Stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) has enrolled its first cohort for its “world first” clinical trial of its stem cell product CYP-001 to treat steroid resistan...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS